Sugi Predict

Sugi Predict / Compounds / SCHEMBL52214

SCHEMBL52214

SCHEMBL52214

O=C(NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ GFER P55789 1/20 0.38
▸ HTR7 P34969 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ ERCC1 P07992 1/20 0.36
▸ FEN1 P39748 1/20 0.36
▸ ERCC4 Q92889 1/20 0.36
▸ CALCA P06881 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52148 0.90 KCNH2 (0.47) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL52808 0.90 CYP2C9 (0.49) KCNH2CYP2C9SMN1; SMN2MAPTERCC1
SCHEMBL52711 0.90 KCNH2 (0.40) KCNH2CYP2C9MAPTCALCAMEN1
SCHEMBL52167 0.90 KCNH2 (0.45) KCNH2CYP2C9GFERSMN1; SMN2MAPT
SCHEMBL52191 0.90 KCNH2 (0.45) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1
SCHEMBL52892 0.90 KCNH2 (0.44) KCNH2CYP2C9TP53SMN1; SMN2LMNA
SCHEMBL52544 0.90 KCNH2 (0.45) KCNH2CYP2C9SMN1; SMN2MAPTLMNA
SCHEMBL52277 0.90 CYP2C9 (0.48) KCNH2CYP2C9SMN1; SMN2MAPTERCC1
SCHEMBL51995 0.89 KCNH2 (0.44) KCNH2CYP2C9SMN1; SMN2LMNAL3MBTL1
SCHEMBL51771 0.89 KCNH2 (0.44) KCNH2CYP2C9SMN1; SMN2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 — — EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 — — US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 — — US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 — — US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 — — US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 — — US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 — — US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885TP53 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.